Sonnet BioTherapeutics, Inc. (NASDAQ:SONN) | WebDisclosure

Switch to English

8296	Sociétés
114905	Mots-clés
55332	Articles
62461	Communiqués

Accueil
Sociétés
Sonnet BioTherapeutics, Inc.

COMMUNIQUÉ DE PRESSE

publié le 29/02/2024 à 22:05, il y a 8 mois 20 jours

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability

Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
COMMUNIQUÉ DE PRESSE

publié le 14/02/2024 à 13:30, il y a 9 mois 7 jours

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023

Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
COMMUNIQUÉ DE PRESSE

publié le 21/12/2023 à 14:00, il y a 10 mois 30 jours

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
COMMUNIQUÉ DE PRESSE

publié le 14/12/2023 à 22:15, il y a 11 mois 6 jours

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
COMMUNIQUÉ DE PRESSE

publié le 31/10/2023 à 12:30, il y a 1 année

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
COMMUNIQUÉ DE PRESSE

publié le 25/10/2023 à 13:30, il y a 1 année

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
COMMUNIQUÉ DE PRESSE

publié le 17/10/2023 à 14:00, il y a 1 année 1 mois

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
COMMUNIQUÉ DE PRESSE

publié le 20/09/2023 à 13:30, il y a 1 année 2 mois

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

Les Echos

Publié le 21/11/2024 à 06:58, il y a 6 heures 56 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 56 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 56 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 47 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 34 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 13:30, il y a 24 minutes

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Publié le 21/11/2024 à 13:30, il y a 24 minutes

Datametrex Secures Additional P.O. Approx $250K for IT Services
Publié le 21/11/2024 à 13:00, il y a 54 minutes

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 54 minutes

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 54 minutes

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 13:41, il y a 13 minutes

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Publié le 21/11/2024 à 13:15, il y a 39 minutes

NOTICE OF ANNUAL GENERAL MEETING
Publié le 21/11/2024 à 12:35, il y a 1 heure 19 minutes

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 39 minutes

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Publié le 21/11/2024 à 12:06, il y a 1 heure 48 minutes

IVU AG publishes Quarterly Report Q3-2024